AstraZeneca drug for rare disease shows promise in flushing copper accumulation

AstraZeneca said on Thursday a late-stage trial showed its medicine for a rare disease that causes accumulation of copper in the body was three times more successful in helping remove deposits from tissues compared with standard care.

The treatment, developed by the drugmaker’s recently acquired Alexion rare diseases unit, was being tested for Wilson disease, a genetic condition in which the body’s ability to remove excess copper is compromised.

For the latest headlines, follow our Google News channel online or via the app.

The experimental oral medicine taken once-daily could provide a less invasive option for patients who are typically given treatments which involve injecting a metal removing solution into the blood or zinc therapy.

“As we advance this first innovation in Wilson disease treatment in more than 30 years, we will continue to follow these patients long term to further assess clinical impact on disease symptoms,” Alexion Chief Executive Officer Marc Dunoyer said.

Copper build-up can cause liver disease and psychiatric or neurological symptoms, such as personality changes, tremors, and difficulty in walking, swallowing, or talking.

The study met the main goal of improvement in the daily mean copper mobilized from tissues over a period of 48 weeks. The treatment has been given an “Orphan Drug” status in the United States and European Union to help speed up development.

Read more: AstraZeneca’s new antibody treatment therapy prevents COVID-19: Study